Basilea announces distribution agreement with Unimedic for CRESEMBA(R) (isavuconazole) and Zevtera(R) (ceftobiprole) in the Nordic countries
September 20, 2016 01:18 ET
|
Basilea Pharmaceutica Ltd.
BASEL, Switzerland, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license and...
Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA(R) (isavuconazole) and Zevtera(R) (ceftobiprole) in Latin America
September 13, 2016 01:24 ET
|
Basilea Pharmaceutica Ltd.
BASEL, Switzerland, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a supply,...
Basilea announces distribution agreement with Hikma for CRESEMBA(r) (isavuconazole) in the MENA region
August 17, 2016 01:19 ET
|
Basilea Pharmaceutica Ltd.
Basilea extending its agreement with Hikma to include antifungal CRESEMBA ® in addition to antibiotic Zevtera ®
BASEL, Switzerland, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Basilea...
Basilea reports 2016 half-year results - CRESEMBA(R) launched in key European markets
August 15, 2016 01:33 ET
|
Basilea Pharmaceutica Ltd.
Antifungal CRESEMBA® (isavuconazole) launched in first European markets
Entered contract with BARDA for the development and potential US registration of the antibiotic ceftobiprole...
Basilea's antifungal CRESEMBA(r) (isavuconazole) launched in Italy
June 27, 2016 01:22 ET
|
Basilea Pharmaceutica Ltd.
BASEL, Switzerland, June 27, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announces that it has launched its new azole antifungal CRESEMBA® (isavuconazole) in Italy and will...
Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA(R) (isavuconazole) open-label study for the treatment of mucormycosis
March 09, 2016 01:19 ET
|
Basilea Pharmaceutica Ltd.
BASEL, Switzerland, March 9, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that results from the open-label phase 3 VITAL study evaluating CRESEMBA®...
Basilea launching antifungal CRESEMBA(R) (isavuconazole) in Germany
March 04, 2016 01:18 ET
|
Basilea Pharmaceutica Ltd.
BASEL, Switzerland, March 4, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) hosts a symposium to support the launch of the new azole antifungal CRESEMBA® (isavuconazole) in...
Basilea launching antifungal CRESEMBA(r) (isavuconazole) in the United Kingdom
March 03, 2016 01:21 ET
|
Basilea Pharmaceutica Ltd.
BASEL, Switzerland, March 3, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) hosts a symposium to support the launch of the new azole antifungal CRESEMBA® (isavuconazole) in the...
Basilea reports solid 2015 full-year results and is launching CRESEMBA(r), its second hospital anti-infective, in Europe
February 29, 2016 01:22 ET
|
Basilea Pharmaceutica Ltd.
CRESEMBA® approval in U.S. and Europe and launched in the U.S. by Astellas
Zevtera® launched in major European countries
Tumor checkpoint controller BAL101553 interim phase 2a...
Basilea announces that European Commission approves isavuconazole (CRESEMBA(r)) as a treatment for invasive aspergillosis and mucormycosis in the European Union
October 16, 2015 10:55 ET
|
Basilea Pharmaceutica Ltd.
Basilea's second anti-infective product approved in Europe, providing potential commercial synergy with Zevtera® (ceftobiprole)
BASEL, Switzerland, Oct. 16, 2015 (GLOBE NEWSWIRE) -- Basilea...